Celldex Approves Equity Plan Amendment and Elects New Director

The latest announcement is out from Celldex ( (CLDX) ).

On June 5, 2025, Celldex Therapeutics held its Annual Meeting of Stockholders, where several key decisions were made, including the approval of an amendment to the 2021 Omnibus Equity Incentive Plan, increasing the shares available for issuance by 2,000,000. Additionally, Denice M. Torres was elected to the Board of Directors, bringing extensive leadership experience from the pharmaceutical and consumer healthcare sectors. The election of new board members and the amendment to the equity plan are expected to bolster Celldex’s strategic growth and operational capabilities as it advances its clinical programs, particularly with the promising drug barzolvolimab.

The most recent analyst rating on (CLDX) stock is a Buy with a $74.00 price target. To see the full list of analyst forecasts on Celldex stock, see the CLDX Stock Forecast page.

Spark’s Take on CLDX Stock

According to Spark, TipRanks’ AI Analyst, CLDX is a Neutral.

Celldex’s strong balance sheet and slight positive technical momentum are overshadowed by its unprofitability and negative cash flow. The lack of earnings call insights and corporate events further limits the stock’s attractiveness. Improvement in profitability and cash flow could enhance the stock’s potential.

To see Spark’s full report on CLDX stock, click here.

More about Celldex

Celldex Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapeutics at the intersection of mast cell biology. Their pipeline includes antibody-based therapeutics aimed at engaging the human immune system to improve the lives of patients with severe inflammatory, allergic, autoimmune, and other devastating diseases.

Average Trading Volume: 869,845

Technical Sentiment Signal: Sell

Current Market Cap: $1.31B

Learn more about CLDX stock on TipRanks’ Stock Analysis page.